Loading
NASDAQHealthcareDrug Manufacturers - General
Latest quote
$0.7455
+$0.0425 · +6.05%
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
Previous close
$0.7455
+$0.0425 · +6.05%
Regular session · ET · Market data may be delayed.
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
Day range
Current $0.7455
52-week range
Current $0.7455
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
29
Expensive
Sentiment
56
Mixed
Risk
76
High Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
Day range
Current $0.7455
52-week range
Current $0.7455
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 1.72M USD | 3.31M USD | 1.57M USD | 2.35M USD | 684.45K USD |
| Selling, general, and administrative | 8.77M USD | 4.71M USD | 6.5M USD | 2.99M USD | 770.12K USD |
| Operating expenses | 10.49M USD | 8.02M USD | 8.53M USD | 7.05M USD | 2.15M USD |
| Interest income | 98.91K USD | — | — | — | — |
| Interest expense | — | 165.67K USD | 3.46M USD | 10.25K USD | 24.37K USD |
| Depreciation and amortization | — | — | — | 7.05M USD | 2.15M USD |
| Operating income | −10.49M USD | −8.02M USD | −8.53M USD | −7.05M USD | −2.15M USD |
| Net income | −10.44M USD | −7.85M USD | −11.98M USD | −7.06M USD | −2.18M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
